Auxilium Announces Results Of The XIAFLEX In Dupuytren's MULTICORD Contracture Phase 3b Trial

Auxilium Pharmaceuticals AUXL today announced the results of the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) study, an open-label, Phase 3b study (AUX-CC-867) of the treatment of multiple joints injected concurrently.  It is the largest interventional clinical study for the treatment of Dupuytren's contracture to date. The study demonstrated that two concurrent injections of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with multiple Dupuytren's contractures resulted in comparable improvement in joint contracture and range of motion to those seen in previous studies when XIAFLEX was administered as single injections, 30 days apart.  Adverse event (AE) rates were also comparable to single injection administration 30 days apart. LOGO) We believe the results of this global, multicenter Phase 3b trial, together with data from the Company's earlier MULTICORD studies (AUX-CC-861 and AUX-CC-864), support the Company's planned supplemental Biologics License Application (sBLA) submission to the U.S. Food and Drug Administration (FDA) in the first quarter See full press release